Antisense oligonucleotide therapy and biomarker assay for C9ORF72 hexanucleotide expansion disorders
Generated by an autonomous AI research agent — Anthropic Claude Opus 4.7 or OpenAI GPT-5.5, max reasoning effort. Sources cited inline. Full disclosure at /methodology/jhtv-deep-dive.
Indication
Frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) / C9ORF72 hexanucleotide expansion disorders
Modality
Nucleic Acid
Mechanism
antisense oligonucleotide (ASO) therapy
Target
C9ORF72
rNPV Envelope
Low
-$11.8M
costs +25% · peak −25%
Base
-$9.4M
cumulative PoS 0.1%
High
-$7.0M
costs −25% · peak +25%
This is an explicitly hypothetical, conservative illustrative profile shown only for cohort rNPV-envelope consistency — it is NOT a fundable-product forecast. Costs/durations are anchored at the LOW end of the biomarker-assay / diagnostic-codevelopment archetype (Simoa poly(GP) trial-ready assay), not a therapeutic ASO program, because the granted in-force JHU IP is a pharmacodynamic monitoring method. PoS values are deliberately depressed below ASO-class priors because the two best-resourced same-target therapeutic ASO programs (BIIB078, WVE-004) both failed Phase 1 with target engagement but no clinical benefit; the only commercializable value here is biomarker/companion-diagnostic licensing, for which the 'phase' nomenclature is a forced cohort mapping rather than a real clinical plan.
Composite score breakdown
Locked rubric — 40/30/30 weights
Clinical relevance · 40%
0.90
Modality fit · 30%
0.27
Whitespace · 30%
0.50
Composite 0.591 — composite-score rank #28 of 50 top-tier inventions in the jhtv-portfolio@2026-Q2 cohort. The page header uses rNPV rank (#5) to match the index ordering.
Comparators
Real programs anchoring the engine inputs
BIIB078 / tadnersen (Biogen / Ionis) — C9ORF72-targeting ASO
Same target (C9ORF72), same modality (intrathecal ASO), same indication (C9orf72-ALS). DESCENDS FROM THIS EXACT IP LINEAGE: Ionis co-inventors Bennett and Freier are on the JHU patent family (WO2014062736A1) and the foundational Donnelly/Sattler/Rothstein 2013 Neuron ASO work. Phase 1 (n=106, intrathecal) reported March 2022: well-tolerated but met NO secondary efficacy endpoint and the 90 mg cohort trended toward GREATER decline than placebo. Program, including the open-label extension, was discontinued. CAUTIONARY PRECEDENT ONLY — it is the strongest available evidence that simple C9ORF72 knockdown does not translate to clinical benefit, which is precisely why the therapeutic half of this asset is not a fundable standalone product.
Criterion 1 (same target + same mechanism + same modality + same indication) and direct IP-lineage descendant. Status: DISCONTINUED (March 2022, Phase 1 negative) — used as a labelled cautionary precedent, not a live anchor.
WVE-004 (Wave Life Sciences) — stereopure C9ORF72 ASO
Independent, differentiated-chemistry same-target program. FOCUS-C9 Phase 1b/2a topline (May 2023) showed robust, sustained poly(GP) reduction (maximal mean 48% and 50%) but NO clinical benefit at 24 weeks and no association between poly(GP) lowering and functional stabilization. Wave discontinued the program citing the absence of biomarkers reasonably likely to predict clinical outcome. Confirms the BIIB078 read-out with orthogonal chemistry: target-engagement biomarker movement without clinical benefit. CAUTIONARY PRECEDENT ONLY.
Criterion 1 (same target, same modality, same indication). Status: DISCONTINUED (May 2023, Phase 1b/2a negative) — cautionary precedent, not a live anchor. Notably its failure is the explicit motivation for the value of a validated pharmacodynamic biomarker.
Simoa / Quanterix trial-ready poly(GP) CSF immunoassay (Rothstein/Sattler-collaborating groups)
Real, published archetype anchor for what this asset's GRANTED, in-force IP actually is — a pharmacodynamic / target-engagement biomarker assay for C9ORF72-repeat disorders, not a therapeutic. The ultrasensitive Simoa poly(GP) CSF assay reported 100% sensitivity / 100% specificity in cohort (poly(GP) detectable in all C9orf72 carriers, undetectable in controls) and is explicitly positioned as trial-ready for assessing target engagement of C9ORF72-lowering therapeutics. This is the closest real development archetype for the asset's commercializable claim set; it is an archetype/cost anchor, NOT a product-revenue comparator.
Archetype anchor (nearest real development path for the granted biomarker-monitoring patent). Status: ACTIVE research/clinical-tool category. Cited as an archetype, not a drug comparator.
Qalsody / tofersen (Biogen) — SOD1 ASO, NfL-biomarker accelerated approval
Active, approved regulatory precedent for the value of a validated fluid biomarker in genetic ALS: tofersen received US accelerated approval in April 2023 on the strength of neurofilament light (NfL) reduction as a surrogate, after its pivotal VALOR primary clinical endpoint was not met. Directly germane because it establishes (a) that a CSF-deliverable ASO can reach approval in genetic ALS and (b) that a credible, qualified pharmacodynamic biomarker is the gating asset for this entire therapeutic class — which is exactly the licensable value of this JHU invention's biomarker half. Cited as a regulatory-pathway and biomarker-value precedent, not a same-target revenue comparator.
Criterion 3 (same regulatory pathway / same modality class in genetic ALS). Status: ACTIVE / APPROVED. Used to anchor the regulatory-precedent and biomarker-value argument, not product economics.
Stage profile
Asset-specific cost, duration, and PoS by stage
| Stage | Cost | Duration | PoS | Citations |
|---|---|---|---|---|
| Preclinical | $4.0M | 18 mo | 45.0% | [0] [4] [5] |
| Phase I | $10.0M | 14 mo | 30.0% | [1] [2] [6] |
| Phase II | $20.0M | 24 mo | 18.0% | [2] [3] [6] |
| Phase III | $35.0M | 30 mo | 12.0% | [2] [3] [7] |
| NDA/BLA Review | $8.0M | 12 mo | 50.0% | [5] [7] |
Multiplier handling: Eligible multipliers (genetic_validation_documentation_only, biomarker_documentation_only) are already reflected in Day-1 comparator-calibrated PoS. Re-applying them via log-odds stacking would double-count, so per-stage PoS is taken as final. See methodology for the rule.
Peak revenue and discount rate
$25.0M peak · WACC 12.0%
Peak revenue. Not a therapeutic product peak. The figure is a conservative, explicitly-illustrative non-commercial / licensing envelope for the asset's actual value path: out-licensing a qualified C9ORF72 pharmacodynamic / target-engagement biomarker assay to ALS/FTD trial sponsors and CROs and as a potential companion diagnostic if any next-generation C9ORF72 (or DPR-directed) therapeutic ever reaches registration. Diagnostic / biomarker-assay licensing economics in a rare neurogenetic population are an order of magnitude below therapeutic peaks; ~$25M reflects cumulative trial-services and modest royalty/milestone potential, not drug revenue. Per the 24284 grant_non_commercial precedent, the rNPV is not the decision criterion for this asset — the number exists only for cohort-envelope consistency.
WACC. A standard placeholder discount rate for cohort-envelope consistency only; WACC is not the operative valuation lever for a non-commercial / licensing-path biomarker-assay asset, so no risk-tier adjustment is applied.
Sensitivity (tornado)
Top drivers of rNPV variance
Drivers ranked by absolute rNPV swing. The vertical tick inside each bar marks the base rNPV (-$9.4M); each bar spans the rNPV range produced by flexing one input between its low and high values. Gold = the input pushes rNPV up when increased; red = the input pushes rNPV down when increased.
Monte Carlo distribution
1,000 trials · rpNPV mode
This is a bimodal distribution by construction, not a Gaussian. Most paths terminate in clinical failure (red cluster — accumulated cost only); a minority succeed and capture full peak revenue (green tail). Bar heights are square-root-scaled so the success tail stays visible alongside the much taller failure cluster; exact counts are preserved in the percentiles below. Gold line = median (P50). Navy dashed = base rNPV (mean) — the probability-weighted expected value, which can sit above the median when the upper tail is strong enough to outweigh the failure cluster (and close to the median when it isn’t).
P5
-$29.5M
P25
-$12.1M
P50 (median)
-$6.3M
P75
-$3.0M
P95
-$1.5M
Prob ≥ 0
0.1%
Evidence register
8 per-assumption citations
| Assumption | Source | Date | Confidence |
|---|---|---|---|
Asset IP lineage and granted-claim scope (JHU + Ionis; biomarker-monitoring methods) cmo_findings.asset_class_reality | WO2014062736A1 — Methods for monitoring c9orf72 expression (inventors Bennett, Freier, Rothstein, Donnelly, Sattler; assignees Johns Hopkins University, Isis/Ionis Pharmaceuticals) regulatory | 2014-04-24 | high |
Granted, in-force US patent is the C9ORF72-expression monitoring method (the asset's commercializable substance) peak_revenue_usd | US10577604B2 — Methods for monitoring c9orf72 expression (granted US patent) regulatory | 2020-03-03 | high |
Foundational JHU ASO discovery this IP descends from stage_profile.preclinical.pos | Donnelly et al., RNA toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention, Neuron 2013 peer_review | 2013-10-16 | high |
Same-target therapeutic ASO (BIIB078, direct IP descendant) failed Phase 1 — therapeutic PoS depressed stage_profile.phase_1.pos | Biogen and Ionis Announce Topline Phase 1 Study Results of Investigational Drug in C9orf72 Amyotrophic Lateral Sclerosis company_filing | 2022-03-28 | high |
BIIB078 program discontinuation (comparator status = stale/cautionary) comparators[0] | Development of ALS Therapy BIIB078 Halted for Lack of Benefit news | 2022-03-30 | high |
Independent same-target ASO (WVE-004) achieved poly(GP) knockdown but no clinical benefit — confirms target-engagement≠benefit stage_profile.phase_2.pos | Wave Life Sciences Announces Topline Results from Phase 1b/2a FOCUS-C9 Study of WVE-004 company_filing | 2023-05-23 | high |
WVE-004 discontinuation (comparator status = stale/cautionary) comparators[1] | ALS therapy WVE-004 ceasing development after study failure news | 2023-05-24 | high |
The asset's real value path: trial-ready C9ORF72 poly(GP) pharmacodynamic biomarker assay stage_profile.nda_bla.pos | Development of a sensitive trial-ready poly(GP) CSF biomarker assay for C9orf72-associated FTD and ALS peer_review | 2022-01-01 | high |
Thesis
Why this asset earns its rank
This JHU invention is not a fundable standalone therapeutic. It is the origin IP of the C9ORF72 antisense field: the patent family (WO2014062736A1; granted US 10,577,604 B2, in force to 2033) names Rothstein, Donnelly and Sattler alongside Ionis's Bennett and Freier and traces directly to the foundational Donnelly 2013 Neuron paper that first showed C9ORF72 repeat-RNA toxicity is mitigated by ASOs. The therapeutic half of that concept already left the building — it was developed by Ionis/Biogen as BIIB078 (tadnersen), which failed Phase 1 in 2022 (no efficacy endpoint met; the high-dose cohort trended worse than placebo) and was discontinued; the independent, differently-engineered Wave program WVE-004 then knocked poly(GP) down ~50% with still no clinical benefit and was discontinued in 2023. What remains JHU-owned, granted and in force is principally the C9ORF72-expression / poly(GP) pharmacodynamic monitoring method: an enabling clinical-trial biomarker tool, plus a hypothetical next-generation ASO concept the field has twice clinically falsified in its simplest form. The asset is therefore classified enabling_technology, the modality bucket is left pinned, and rNPV of a product does not apply.
Economically the honest anchor is not a drug peak but the biomarker-assay archetype: a trial-ready Simoa poly(GP) CSF assay (100% sensitivity/specificity in cohort) is the nearest real development path, and tofersen/Qalsody's 2023 NfL-biomarker accelerated approval is the regulatory precedent showing that a qualified fluid biomarker — not a knockdown ASO per se — is the gating asset for genetic-ALS development. The engine result is -$11.8M to -$7.0M, with a base rNPV of -$9.4M and cumulative PoS of 0.1%; that spread is shown only for cohort consistency and should be read as a licensing/non-commercial illustration, not an equity case — the value path is out-licensing the qualified pharmacodynamic assay to ALS/FTD trial sponsors and as a potential companion diagnostic, with royalty/milestone economics an order of magnitude below any therapeutic peak.
Verdict: a credibility-grade, founding-IP biomarker enabling technology, not a venture-fundable drug — which is exactly why it is classified grant_non_commercial. It earns rank 28 on rubric clinical-relevance (a Mendelian, no-disease-modifying-therapy genetic ALS/FTD target) plus the neutral 0.5 'other'-indication whitespace and the nucleic-acid modality_pos, not on being a fundable product; the rNPV is explicitly not the decision criterion here.
Key risks
Asset-specific, not generic biotech risks
- Therapeutic thesis twice clinically falsified: BIIB078 (a direct descendant of this exact JHU/Ionis IP) and the orthogonal-chemistry WVE-004 both achieved target engagement but no clinical benefit and were discontinued (2022, 2023). Any new C9ORF72-knockdown ASO inherits a strongly negative class prior — the therapeutic half is not independently fundable.
- Asset-class / value-path risk: the granted, in-force JHU claim set is a biomarker-monitoring method, not a therapeutic composition; valuing this as a drug is a category error. Value depends on out-licensing a pharmacodynamic/companion-diagnostic assay, a far smaller and royalty-driven economic envelope.
- Biomarker-disconnect risk undermines even the assay value: WVE-004 showed ~50% poly(GP) lowering with no functional benefit, so poly(GP) is a validated target-engagement marker but NOT a validated surrogate for clinical outcome — limiting its standalone regulatory leverage absent a working therapeutic.
- Modality-bucket vs reality: the pinned 'nucleic_acid' bucket does not reflect that the commercializable, granted IP is a diagnostic assay; the bucket is retained per methodology but the mismatch is disclosed and must not be read as a therapeutic-ASO valuation.
- Competitive/IP timing: C9ORF72 ASO therapeutic IP is crowded (Ionis/Biogen, Wave) and the foundational therapeutic approach is now widely viewed as de-risked-negative; the durable JHU position is the monitoring-method patent (expiry 2033), whose value erodes if no next-generation C9ORF72/DPR therapeutic ever advances to need a companion assay.